US Drug Recall Register

Is Cyclophosphamide recalled?

Yes — there is an active recall. 3 ongoing FDA recalls mention Cyclophosphamide (8 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Cyclophosphamide. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed.

Class I · High risk Ongoing

Cyclophosphamide for Injection

Reason Presence of Particulate Matter; identified as stainless steel

Sunny Pharmtech Inc. NDC 81298-8114-1 D-0744-2026
Class I · High risk Ongoing

Cyclophosphamide for Injection

Reason Presence of Particulate Matter; identified as stainless steel

Sunny Pharmtech Inc. NDC 81298-8112-1 D-0743-2026
Class II · Moderate risk Ongoing

Cyclophosphamide Injection 500 mg/5 mL

Reason cGMP deviations: Temperature excursion during transportation.

Sandoz Inc NDC 0781-3528-75 D-0651-2025
Class III · Low risk Terminated

Cyclophosphamide for Injection

Reason Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

X-Gen Pharmaceuticals Inc. NDC 39822-0255-01 D-0434-2024
Class III · Low risk Terminated

Cyclophosphamide for Injection

Reason Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

X-Gen Pharmaceuticals Inc. NDC 39822-0250-01 D-0433-2024
Class II · Moderate risk Terminated

Cyclophosphamide Monohydrate active pharmaceutical ingredient…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-606-2015